Drug Profile
Nanocurcumin - JYANT Technologies
Latest Information Update: 11 Dec 2021
Price :
$50
*
At a glance
- Originator JYANT Technologies
- Class Anti-ischaemics; Antihistamines; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Cyclo-oxygenase 2 inhibitors; Cystic fibrosis transmembrane conductance regulator modulators; Immunosuppressants; Mast cell stabilisers; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis; Solid tumours
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in USA
- 28 Sep 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA
- 12 Aug 2016 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)